IngSilico Medicine Swings to $33.5–39.5M Profit in H1 2026, Shares Up 8.3%

According to its guidance, IngSilico Medicine expects H1 2026 net profit of $33.5–39.5 million, reversing a loss of $19.2 million in the same period last year. Revenue is projected at $103–107 million, up 2.73–2.87 times year-over-year, driven largely by increased income from licensing, co-development and research collaboration agreements, as well as operational efficiency improvements.

Shares rose 8.3% to HK$40.06 as of 10:15 a.m., with intraday gains reaching 9.8% to HK$40.62, on trading volume exceeding HK$460 million.